Trial Profile
A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Tovorafenib (Primary)
- Indications CNS cancer; Glioma; Neurofibromatoses; Solid tumours
- Focus Adverse reactions
- 13 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Nov 2021 According to a Day One Biopharmaceuticals media release, this study is sponsored by the Dana-Farber Cancer Institute.
- 19 Nov 2020 According to a Day One Biopharmaceuticals media release, DAY101 has been granted Breakthrough therapy designation by the FDA for the treatment of pediatric patients with an advanced low-grade glioma harboring an activating RAF alteration who require systemic therapy and who have either progressed following prior treatment or who have no satisfactory alternative treatment options, based on all of the available clinical data from the DAY101 development program, including this study.